These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 6543135)

  • 21. Sustained-release isosorbide mononitrate (50 mg): optimization of a once-daily dosage form for long-term treatment of angina pectoris.
    Bonn R
    Am J Cardiol; 1988 Mar; 61(9):12E-14E. PubMed ID: 3348135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation.
    Gandini R; Cunietti E; Assereto R; Castoldi D; Tofanetti O; Baggio E
    Arzneimittelforschung; 1987 Jul; 37(7):836-9. PubMed ID: 3675680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration.
    Abshagen U; Betzien G; Endele R; Kaufmann B; Neugebauer G
    Eur J Clin Pharmacol; 1985; 27(6):637-44. PubMed ID: 3987768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
    Parker JO
    Can J Cardiol; 1991 Apr; 7(3):125-30. PubMed ID: 2044014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between the pharmacodynamics and pharmacokinetics of two oral sustained-release formulations of isosorbide dinitrate in normal man.
    Johnson KI; Gladigau V; Schnelle K
    Arzneimittelforschung; 1981; 31(6):1026-9. PubMed ID: 7196234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma isosorbide dinitrate concentrations and effect after chewable and high-dose, sustained-release formulations.
    Galeazzi RL; Platzer R; Reutemann G
    Int J Clin Pharmacol Ther Toxicol; 1983 Aug; 21(8):387-93. PubMed ID: 6629543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms].
    Merz PG; Thürmann P; Harder S
    Arzneimittelforschung; 1992 Jan; 42(1):21-4. PubMed ID: 1586375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Newer aspects of the pharmacokinetics of organic nitrates.
    Chasseaud LF
    Z Kardiol; 1983; 72 Suppl 3():20-3. PubMed ID: 6666223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate.
    Sata H; Inoue K; Nii T; Kuroda T
    Biol Pharm Bull; 1997 Oct; 20(10):1111-5. PubMed ID: 9353575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized crossover trial of isosorbide mononitrate (Elantan 20) and slow-release glyceryl trinitrate in the treatment of angina pectoris.
    Brodie NH; O'Hara H; O'Hara J; Valle-Jones JC
    Pharmatherapeutica; 1985; 4(6):367-75. PubMed ID: 3936056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers.
    Hutt V; Theodor R; Pabst G; Lutz D; Bonn R; Fritschi E
    Arzneimittelforschung; 1993 Aug; 43(8):842-6. PubMed ID: 8216439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single and multiple dose pharmacokinetic studies of oral sustained release and non-sustained release formulations of isosorbide-5-mononitrate in healthy volunteers.
    Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
    Arzneimittelforschung; 1998 Jun; 48(6):641-5. PubMed ID: 9689420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing.
    Straehl P; Galeazzi RL; Soliva M
    Clin Pharmacol Ther; 1984 Oct; 36(4):485-92. PubMed ID: 6478734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the pharmacokinetics and absolute bioavailability of three isosorbide-5-mononitrate preparations in healthy volunteers.
    Hutt V; Bonn R; Fritschi E; Jaeger H
    Arzneimittelforschung; 1995 Feb; 45(2):142-5. PubMed ID: 7710435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation.
    Chasseaud LF; Doyle E; Taylor T; Darragh A
    Biopharm Drug Dispos; 1981; 2(3):273-81. PubMed ID: 7295884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and bioavailability of isosorbide-5-mononitrate in humans.
    Rameis H; Bacher S; Eichler HG; Horwatitsch H
    Int J Clin Pharmacol Ther Toxicol; 1985 Dec; 23(12):678-80. PubMed ID: 4093207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the initial hemodynamic effects of immediate-release versus sustained-release isosorbide-5-mononitrate following single oral doses.
    Trenk D; Hinder M; Stengele E; Bonn R; Jähnchen E
    J Clin Pharmacol; 2000 Feb; 40(2):168-76. PubMed ID: 10664923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical chronopharmacology of oral sustained-release isosorbide-5-mononitrate in healthy subjects.
    Lemmer B; Scheidel B; Blume H; Becker HJ
    Eur J Clin Pharmacol; 1991; 40(1):71-5. PubMed ID: 2060550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Intraindividual dose-response relationship of sustained-release Elantan].
    Kenedi P
    Z Kardiol; 1986; 75 Suppl 3():77-9. PubMed ID: 3541420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The pharmacokinetics and bioequivalence of acipimox sustained-release tablets after a single and multiple oral administration in healthy dogs].
    Yang XG; Nie SF; Bai HJ; Zhang GJ; Pan WS
    Yao Xue Xue Bao; 2005 May; 40(5):457-61. PubMed ID: 16220793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.